These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28930775)

  • 21. Phase I dose escalation study of docetaxel with a fixed dose of S-1 in combination chemotherapy for advanced gastric cancer.
    Kim YH; Seo HY; Jeen YT; Kim HK; Shim BY; Yang J
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):253-60. PubMed ID: 18493761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term outcomes of preoperative docetaxel with cisplatin plus S-1 therapy for gastric cancer with extensive nodal metastasis (JCOG1002).
    Takahari D; Ito S; Mizusawa J; Katayama H; Terashima M; Sasako M; Morita S; Nomura T; Yamada M; Fujiwara Y; Kimura Y; Ikeda A; Kadokawa Y; Sano T;
    Gastric Cancer; 2020 Mar; 23(2):293-299. PubMed ID: 31515693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
    Yoshida K; Ninomiya M; Takakura N; Hirabayashi N; Takiyama W; Sato Y; Todo S; Terashima M; Gotoh M; Sakamoto J; Nishiyama M
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3402-7. PubMed ID: 16740764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer.
    Choi IS; Lee KW; Kim KH; Kim YJ; Kim JH; Lee JS
    Med Oncol; 2010 Sep; 27(3):992-7. PubMed ID: 20077040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.
    Takayama T; Sato Y; Sagawa T; Okamoto T; Nagashima H; Takahashi Y; Ohnuma H; Kuroiwa G; Miyanishi K; Takimoto R; Matsunaga T; Kato J; Yamaguchi K; Hirata K; Niitsu Y
    Br J Cancer; 2007 Oct; 97(7):851-6. PubMed ID: 17848958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial.
    Roth AD; Maibach R; Fazio N; Sessa C; Stupp R; Morant R; Herrmann R; Borner MM; Goldhirsch A; de Braud F
    Ann Oncol; 2004 May; 15(5):759-64. PubMed ID: 15111343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
    Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
    Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 in patients with advanced gastric cancer.
    Kimura Y; Yano H; Imamura H; Fujitani K; Imano M; Tokunaga Y; Matsuoka M; Kurokawa Y; Shimokawa T; Takiuchi H; Tsujinaka T; Furukawa H
    Jpn J Clin Oncol; 2013 Feb; 43(2):125-31. PubMed ID: 23225911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer.
    Hirahara N; Matsubara T; Kaji S; Yamamoto T; Hyakudomi R; Takai K; Ishitobi K; Uchida Y; Tajima Y
    BMC Cancer; 2021 Oct; 21(1):1073. PubMed ID: 34598694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer.
    Park KW; Ahn JS; Park YS; Lee J; Kang JH; Park JO; Lim HY; Im YH; Kang WK; Park K; Lee SI
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):17-21. PubMed ID: 16721549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
    Inada S; Tomidokoro T; Fukunari H; Sato T; Hatano T; Nishimura A; Kawauchi Y; Nikkuni K; Shimizu T; Sato T; Yanagi M; Takahashi S; Yoshida H; Sugita M; Hayashi T
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):267-73. PubMed ID: 18379784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer.
    Yamaguchi K; Shimamura T; Hyodo I; Koizumi W; Doi T; Narahara H; Komatsu Y; Kato T; Saitoh S; Akiya T; Munakata M; Miyata Y; Maeda Y; Takiuchi H; Nakano S; Esaki T; Kinjo F; Sakata Y
    Br J Cancer; 2006 Jun; 94(12):1803-8. PubMed ID: 16773074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma.
    Ajani JA; Lee FC; Singh DA; Haller DG; Lenz HJ; Benson AB; Yanagihara R; Phan AT; Yao JC; Strumberg D
    J Clin Oncol; 2006 Feb; 24(4):663-7. PubMed ID: 16446338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study.
    Seol YM; Song MK; Choi YJ; Kim GH; Shin HJ; Song GA; Chung JS; Cho GJ
    Jpn J Clin Oncol; 2009 Jan; 39(1):43-8. PubMed ID: 18997184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of docetaxel and cisplatin plus S-1 for advanced gastric cancer.
    Luo H; Yu Z; Gao H; Guan C; Xu M
    J BUON; 2013; 18(1):154-61. PubMed ID: 23613401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Docetaxel plus S-1 versus cisplatin plus S-1 in unresectable gastric cancer without measurable lesions: a randomized phase II trial (HERBIS-3).
    Kurokawa Y; Matsuyama J; Nishikawa K; Takeno A; Kimura Y; Fujitani K; Kawabata R; Makari Y; Terazawa T; Kawakami H; Sakai D; Shimokawa T; Satoh T
    Gastric Cancer; 2021 Mar; 24(2):428-434. PubMed ID: 32779034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I/II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer.
    Kim KH; Park YS; Chang MH; Kim HS; Jun HJ; Uhm J; Yi SY; Lim DH; Ji SH; Park MJ; Lee J; Park SH; Park JO; Lim HY; Kang WK
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):347-53. PubMed ID: 19066894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Performance of outpatient regimen of S-1 in combination with fractional cisplatin for advanced or recurrent gastric cancers: a phase I study.
    Shimoyama S; Imamura K; Hiki N; Yamaguchi H; Mafune K; Kaminishi M
    Int J Clin Oncol; 2005 Aug; 10(4):251-5. PubMed ID: 16136370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of cetuximab plus S-1/cisplatin therapy in Japanese patients with advanced gastric cancer.
    Yamaguchi K; Fuse N; Komatsu Y; Fujii H; Hironaka S; Omuro Y; Muro K; Yasui H; Ueda S; Nishina T; Watanabe M; Ohtsu A
    Jpn J Clin Oncol; 2021 May; 51(6):879-885. PubMed ID: 33561262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Prospective Phase I/II Study of Docetaxel, Cisplatin and Continuous Capecitabine in Advanced Oesophago-Gastric Cancer (NWCOG-3).
    Gollins S; Massalha S; Mullard A; Williams RM; Lloyd A; Morris J; Garcia-Alonso A
    Clin Oncol (R Coll Radiol); 2018 Jul; 30(7):409-417. PubMed ID: 29573846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.